Myelin oligodendrocyte glycoprotein antibody-associated disease presents complex clinical questions for reproductive-age women and their treating physicians. When patients with this autoimmune central nervous system condition conceive, questions naturally arise regarding transplacental antibody transfer and lactation safety. A landmark case report offers crucial immunological insights into how maternal MOG autoantibodies behave during pregnancy and lactation. This evidence provides immense clinical reassurance for clinicians counseling new mothers who wish to breastfeed safely.

Longitudinal Dynamics of Maternal MOG Autoantibodies

In this comprehensive investigation, clinicians monitored maternal serum antibody titers longitudinally across pregnancy and the postpartum period. Consequently, researchers documented persistently elevated maternal circulating titers, with an interesting transient reduction during early pregnancy. This temporary decline reflects the natural maternal-fetal immune tolerance mechanisms typical of early gestation. Furthermore, cell-based assays confirmed that immunoglobulin levels rebounded robustly as pregnancy advanced toward delivery and into the postpartum window. Detailed subclass analysis revealed that maternal MOG autoantibodies were restricted exclusively to the IgG1 and IgA1 subclasses. Moreover, epitope specificity assays and isoform recognition panels demonstrated remarkable stability over time. The binding profile did not alter substantially between early gestation and subsequent lactation. Therefore, the longitudinal data show that while systemic disease titers remain high, immunological profiles remain predictable throughout gestation. These biological insights help neurologists understand how humoral autoimmunity interacts with physiological hormonal fluctuations during and immediately after pregnancy.

Detection of MOG-IgG and MOG-IgA in Breast Milk

A critical highlight of this investigation centers on the mammary secretion of autoantibodies. The study demonstrated the concurrent presence of both MOG-specific IgG and MOG-specific IgA within mature breast milk samples. Notably, the binding patterns to MOG isoforms and target epitopes matched the maternal plasma compartments almost identically. This finding indicates that specific maternal antibodies traverse the blood-milk barrier through active physiological mechanisms. Specifically, the neonatal Fc receptor and related transport pathways facilitate immunoglobulin secretion into colostrum and breast milk. Because immunoglobulin G1 and immunoglobulin A1 dominate human milk immunoglobulins, their presence reflects standard humoral secretion rather than abnormal barrier breakdown. However, while autoantibodies entered breast secretions, the absolute concentrations remained substantially lower than circulating maternal blood titers. Consequently, breast milk acts as a conduit for physiological antibody delivery without concentrating pathogenic autoantibodies abnormally. Understanding this transport mechanism clarifies the biological reality of neuroimmunological conditions during ongoing lactation.

Transplacental Transfer Versus Infant Systemic Absorption

The investigators also examined infant blood at delivery and longitudinally over eighteen months. At birth, the infant tested positive for circulating MOG-IgG, demonstrating efficient transplacental maternal-fetal antibody transfer mediated by the syncytiotrophoblast. However, infant blood showed negative results for MOG-IgA, as expected with classic placental immunoglobulin filtration. Crucially, although the neonate ingested MOG-positive milk continually across eighteen months of breastfeeding, systemic absorption through the mature gut remained negligible. The human neonatal digestive tract quickly digests or excretes ingested immunoglobulins instead of transferring intact macromolecules into circulation. Furthermore, intact immunoglobulin molecules cannot readily cross an intact infant blood-brain barrier. Therefore, maternal autoantibodies cannot reach target myelin antigens within the developing central nervous system. These physiological biological barriers protect the developing child from maternal autoimmune activity. This mechanistic understanding explains why circulating maternal antibodies do not automatically translate into infant neuroinflammatory damage.

Reassuring Clinical Outcomes in Exposed Infants

Most importantly for practicing clinicians, the infant remained entirely asymptomatic throughout the eighteen-month follow-up period. The pediatric team observed normal developmental milestones, normal visual acuity, and no neurological deficits whatsoever. Despite continuous exposure through nursing, the child showed zero evidence of optic neuritis, acute disseminated encephalomyelitis, or transverse myelitis. Furthermore, longitudinal pediatric evaluations confirmed robust physical and cognitive maturation. This favorable outcome corroborates emerging evidence showing that passively transferred MOG antibodies do not trigger clinical neuroinflammation. Because endogenous active antibody production differs fundamentally from passive maternal transfer, disease manifestations do not typically manifest in infants. Consequently, the presence of circulating maternal antibodies represents transient seropositivity rather than active neonatal autoimmunity. Pediatricians can therefore distinguish between benign antibody carriage and true pathological illness. This clinical outcome brings enormous peace of mind to anxious mothers managing complex neuroimmune conditions.

Clinical Guidance for Counseling Breastfeeding Mothers

These findings carry immediate, practical relevance for obstetricians, neurologists, and pediatric healthcare teams. Historically, concerns over autoantibody transmission prompted physicians to advise against breastfeeding in mothers with autoimmune demyelinating disease. However, contemporary evidence demonstrates that maternal MOG autoantibodies do not cause neonatal neurological dysfunction. Therefore, healthcare providers should actively encourage and support breastfeeding in stable mothers diagnosed with this condition. Clinicians should nevertheless design coordinated multidisciplinary care plans that unite adult neurology, obstetrics, and neonatology. If a mother requires postpartum immunotherapy, physicians must choose disease-modifying agents compatible with lactation. Corticosteroids, high-dose intravenous immunoglobulins, and selected monoclonal antibodies often permit safe infant nursing. Meanwhile, pediatricians should conduct standard routine developmental surveillance without unnecessary invasive testing. By adopting this balanced, evidence-based strategy, clinicians preserve the invaluable benefits of human milk while safeguarding maternal health.

Does the detection of maternal MOG autoantibodies in breast milk cause MOGAD in the nursing infant?

No, clinical evidence demonstrates that maternal antibodies in breast milk do not cause disease in the infant. Although MOG-IgG and MOG-IgA enter breast milk, the infant digestive system breaks down these immunoglobulins. Furthermore, intact antibodies cannot penetrate the infant blood-brain barrier to target central myelin. In clinical studies, exposed infants remained completely asymptomatic with normal neurological development throughout eighteen months of nursing follow-up.

Should mothers diagnosed with MOGAD avoid breastfeeding their newborn children?

Mothers with MOGAD do not need to avoid breastfeeding based purely on antibody transfer concerns. Current data show that breast milk antibody exposure does not induce neonatal neuroinflammation or developmental harm. However, clinicians must evaluate maternal disease activity and the compatibility of any prescribed disease-modifying therapies. If mothers receive compatible postpartum treatments such as intravenous immunoglobulin or safe steroids, breastfeeding remains safe, beneficial, and medically recommended.

How does transplacental transmission of MOG-IgG differ from exposure through breast milk?

Transplacental transfer delivers maternal IgG directly into fetal circulation across the placenta during pregnancy, producing detectable infant blood titers at birth. In contrast, breastfeeding delivers antibodies solely into the infant gastrointestinal lumen. The infant digestive mucosa degrades these ingested proteins, preventing significant systemic absorption into maternal or infant circulation. Consequently, breast milk antibodies carry even less theoretical systemic risk than transplacentally acquired immunoglobulins for the developing child.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician or other qualified healthcare provider for guidance regarding a medical condition. Physicians should review all available medical evidence, clinical practice guidelines, and consult with colleagues when necessary to make the best possible treatment decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Majed M et al. Detection of MOG-IgG and MOG-IgA in Maternal Breast Milk and Infant Blood in MOGAD: A Case Report. Neurol Neuroimmunol Neuroinflamm. 2026 Nov undefined. doi: 10.1212/NXI.0000000000200652. PMID: 42854177.
2. Kammermeier S, Heck S, Zimmermann H, et al. Myelin Oligodendrocyte Glycoprotein Antibodies in Breast Milk in a Lactating Woman With Severe Enterovirus-Associated MOGAD. Neurol Neuroimmunol Neuroinflamm. 2026;13(5):e200637. doi:10.1212/NXI.0000000000200637.
3. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Consortium proposed criteria. Lancet Neurol. 2023;22(3):268-282.